The International Congress on
Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Andel’s Hotel, Berlin, Germany, September 8-11, 2011 |
|
| |
| Scientific Program |
 |
|
|
Thursday, September 8, 2011 |
| 19:00-20:30 |
Welcome Reception |
| |
|
|
Friday, September 9, 2011
|
|
HALL A |
|
|
Plenary Session 1
SCT in Myeloma and MDS |
|
Chairs: N. Kröger, Germany & A. Nagler, Israel |
| 08:30-08:35 |
Co-Chairpersons Introduction |
|
|
|
Autologous SCT as first line treatment? |
| 08:35-08:45 |
Yes: J.L. Harousseau, France |
| 08:45-08:55 |
No: J. Blade, Spain |
| 08:55-09:15 |
Discussion |
|
|
|
Allo SCT in elderly patients (>60 y) with MDS |
| 09:15-09:30 |
Yes: N. Kröger, Germany |
| 09:30-09:45 |
No: H.J. Deeg, USA |
| 09:45-10:00 |
Discussion |
|
|
|
|
10:00-10:30 |
Coffee Break |
|
|
|
|
Session 2
Relapse Prevention |
|
Relapse prevention: Prophylactic DLI? |
|
Chair: A.R. Zander, Germany |
| 10:30-10:45 |
Yes: H.J. Kolb, Germany |
| 10:45-11:00 |
No: A. Bacigalupo, Italy |
| 11:00-11:15 |
Discussion |
|
|
|
Can we prevent relapse by novel conditioning regimen? |
|
Chair: S.A. Giralt, USA |
| 11:15-11:30 |
Yes: M. de Lima, USA |
| 11:30-11:45 |
No: A. Shimoni, Israel |
| 11:45-12:00 |
Discussion |
|
|
|
12:00-13:00 |
Lunch Break |
|
|
| 13:00-13:45 |
Special Debate: Is there any place for the prophylactic collection of autologous stem cells for major radiation incidents?
Chair: A. Madrigal, UK |
| 13:00-13:05 |
No: D. Niederwieser, Germany |
| 13:05-13:10 |
Yes: A.S. Shimosaka, Japan |
| 13:10-13:15 |
No: D.M. Weinstock, USA |
| 13:15-13:20 |
Yes: R. Powles, UK |
| 13:20-13:25 |
No: A. Buzyn, France |
| 13:25-13:45 |
Discussion |
|
|
|
13:45-14:00 |
Break |
|
|
|
|
Session 4
Treatment and Prevention of Relapse |
|
Second allo for relapse |
|
Chair: J. Miller, USA |
| 14:00-14:15 |
Yes: S. Slavin, Israel |
| 14:15-14:30 |
No: S.A. Giralt, USA |
| 14:30-14:45 |
Discussion |
|
|
|
Donor selection to prevent relapse |
|
Chair: M. de Lima, USA |
| 14:45-15:00 |
According to KIR typing: J. Miller, USA |
| 15:00-15:15 |
According to HLA typing: A. Madrigal, UK |
| 15:15-15:30 |
Discussion |
|
|
|
15:30-16:00 |
Coffee Break |
|
|
|
|
Session 6
Refractory and Residual Leukemia |
|
Allo SCT for refractory leukemia |
|
Chair: J.M. Rowe, Israel |
| 16:00-16:15 |
Yes: M. Mohty, France |
| 16:15-16:30 |
No: D. Blaise, France |
| 16:30-16:45 |
Discussion |
|
|
|
Should all MRD positive patients receive allo SCT? |
|
Chair: C. Peters, Austria |
| 16:45-17:00 |
Yes: P. Bader, Germany |
| 17:00-17:15 |
No: G. Henze, Germany |
| 17:15-17:30 |
Discussion |
|
|
|
HALL B |
|
|
Session 3
AML and CML |
|
Indication for unrelated allo SCT in 1. CR AML |
|
Chair: M. Mohty, France |
| 10:30-10:45 |
Yes: D. Niederwieser, Germany |
| 10:45-11:00 |
No: I. Yakoub-Agha, France |
| 11:00-11:15 |
Discussion |
|
|
|
Allogeneic SCT for CML after failure to 1. TKI |
|
Chair: R. Hehlmann, Germany |
| 11:15-11:30 |
Yes: E. Olavarria, Spain |
| 11:30-11:45 |
No: J.F. Apperley, UK |
| 11:45-12:00 |
Discussion |
|
|
|
12:00-13:00 |
Lunch Break |
|
|
|
|
Session 5
Aplastic Anemia and Autoimmune Diseases |
|
MUD or immunsuppressive therapy for aplastic anemia |
|
Chair: J. Finke, Germany |
| 14:00-14:15 |
MUD: J.R. Passweg, Switzerland |
| 14:15-14:30 |
IS: A. Bacigalupo, Italy |
| 14:30-14:45 |
Discussion |
|
|
|
Autologous SCT for autoimmune disease |
|
Chair: R. Arnold, Germany |
| 14:45-15:00 |
Yes: D. Farge-Bancel, France |
| 15:00-15:15 |
No: S. Dabadghao, India |
| 15:15-15:30 |
Discussion |
|
|
|
15:30-16:00 |
Coffee Break |
|
|
|
|
Session 7
GvHD Prevention by T-Cell Modulation |
|
Can Treg prevent GvHD without losing GvL? |
|
Chair: E. Holler, Germany |
| 16:00-16:15 |
Yes: M.F. Martelli, Italy |
| 16:15-16:30 |
No:J.L. Ferrara, USA |
| 16:30-16:45 |
Discussion |
|
|
|
Is photopheresis treatment of choice for cGvHD? |
|
Chair: H.J. Deeg, USA |
| 16:45-17:00 |
Yes: H. Greinix, Austria |
| 17:00-17:15 |
No: G. Socié, France |
| 17:15-17:30 |
Discussion |
|
|
|
Saturday, September 10, 2011
|
|
HALL A |
|
|
Session 8
|
|
Is double cord blood to be preferred to a single unit? |
|
Chair: E. Gluckman, France |
| 08:30-08:45 |
Yes: C. Brunstein, USA |
| 08:45-09:00 |
No: V. Rocha, France |
| 09:00-09:15 |
Discussion |
|
|
|
Should cord blood unit be selected according to HLA or cell-based? |
|
Chair: V. Rocha, France |
| 09:15-09:30 |
Cell-based: E. Gluckman, France |
| 09:30-09:45 |
HLA-based: C. Brunstein, USA |
| 09:45-10:00 |
Discussion |
|
|
|
10:00-10:30 |
Coffee Break |
|
|
|
|
Session 10
Donor Selection |
|
Which is the donor of choice if no MUD is available? |
|
Chair: A. Madrigal, UK |
| 10:30-10:45 |
Haplo: L. Uharek, Germany |
| 10:45-11:00 |
Cord blood: W. Arcese, Italy |
| 11:00-11:15 |
Discussion |
|
|
|
Should we expand cord blood? |
|
Chair: W. Arcese, Italy |
| 11:15-11:30 |
Yes: A. Nagler, Israel |
| 11:30-11:45 |
No: V. Rocha, France |
| 11:45-12:00 |
Discussion |
|
|
|
|
Lunch Break |
|
|
| 12:45-14:00 |
Novartis Satellite Symposium
Update and Perspectives on Iron Chelation and Immunotherapy in Transplantation |
| 12:45-12:50 |
Introduction: N. Kröger, Hamburg |
| 12:50-13:10 |
Pathophysiology of Acute GvHD: Innate Meets Adaptive Immunity: E. Holler, Regensburg |
| 13:10-13:30 |
Does Iron Chelation Improve Survival in SCT? H. Al-Ali, Leipzig |
| 13:30-13:50 |
Practical Aspects of an Iron Chelation Therapy in SCT: U. Platzbecker, Dresden |
| 13:50-14:00 |
Summary and Discussion: N. Kröger, Hamburg |
|
|
|
|
|
|
Autologous SCT in FL |
|
Chair: P. Corradini, Italy |
| 14:00-14:15 |
Yes: C. Gisselbrecht, France |
| 14:15-14:30 |
No: U. Dührsen, Germany |
| 14:30-14:45 |
Discussion |
|
|
|
Transplantation for T-cell lymphoma |
|
Chair: C. Gisselbrecht, France |
| 14:45-15:00 |
Pro auto: P. Reimer, Germany |
| 15:00-15:15 |
Pro allo: P. Corradini, Italy |
| 15:15-15:30 |
Discussion |
|
|
|
15:30-16:00 |
Coffee Break |
|
|
|
|
Session 14
Allogeneic SCT for Myeloma and Hodgkin's Disease |
|
Is there a place for allo SCT in treatment of MM? |
|
Chair: N. Kröger, Germany |
| 16:00-16:15 |
Yes: G. Gahrton, Sweden |
| 16:15-16:30 |
No: H. Goldschmidt, Germany |
| 16:30-16:45 |
Discussion |
|
|
|
Is there a place for allo SCT in Hodgkin’s disease? |
|
Chair: U. Dührsen, Germany |
| 16:45-17:00 |
Yes: L. Farina, Italy |
| 17:00-17:15 |
No: V. Diehl, Germany |
| 17:15-17:30 |
Discussion |
|
|
|
HALL B |
|
|
Session 9
Myelofibrosis and Haploidentical Transplantation |
|
Allo SCT for elderly myelofibrosis patients (>60 y) |
|
Chair: A. Bacigalupo, Italy |
| 08:30-08:45 |
Yes: N. Kröger, Germany |
| 08:45-09:00 |
No: R.A. Mesa, USA |
| 09:00-09:15 |
Discussion |
|
|
|
Should haplo-SCT be performed with T-cell depletion? |
|
Chair: Y. Reisner, Israel |
| 09:15-09:30 |
Yes: R. Handgretinger, Germany |
| 09:30-09:45 |
No: F. Ciceri, Italy |
| 09:45-10:00 |
Discussion |
|
|
|
10:00-10:30 |
Coffee Break |
|
|
|
|
|
|
Is specific T-cell therapy targeting mHag useful? |
|
Chair: F. Locatelli, Italy |
| 10:30-10:45 |
Yes: S. Riddell, USA |
| 10:45-11:00 |
No: M. Bornhäuser, Germany |
| 11:00-11:15 |
Discussion |
|
|
|
Gene therapy for genetic diseases (SCID, FA, CGD) |
|
Chair: R. Handgretinger, Germany |
| 11:15-11:30 |
Yes: M. Cavazzana-Calvo, France |
| 11:30-11:45 |
No: I. Müller, Germany |
| 11:45-12:00 |
Discussion |
|
|
|
12:00-13:00 |
Lunch Break |
|
|
|
|
Session 13
T-Cell Depletion and Mesenchymal Stroma Cells |
|
T-cell depletion and T-cell add back |
|
Chair: L. Uharek, Germany |
| 14:00-14:15 |
Yes: J.H.F Falkenburg, The Netherlands |
| 14:15-14:30 |
No: R. Storb, USA |
| 14:30-14:45 |
Discussion |
|
|
|
MSC for GvHD |
|
Chair: M. Bornhäuser, Germany |
| 14:45-15:00 |
Yes: K. Le Blanc, Sweden |
| 15:00-15:15 |
No: F. Locatelli, Italy |
| 15:15-15:30 |
Discussion |
|
|
|
15:30-16:00 |
Coffee Break |
|
|
|
|
Session 15
GvHD Prevention by Antibodies |
|
GvHD prevention |
|
Chair: A.R. Zander, Germany |
| 16:00-16:15 |
Pro ATG: J. Finke, Germany |
| 16:15-16:30 |
Pro Alemtuzemab: S. Mackinnon, UK |
| 16:30-16:45 |
Discussion |
|
|
|
Is it possible to separate GvHD from GvL? |
|
Chair: J.L. Ferrara, USA |
| 16:45-17:00 |
Yes: E. Holler, Germany |
| 17:00-17:15 |
No: H.J. Deeg, USA |
| 17:15-17:30 |
Discussion |
|
|
|
Sunday, September 11, 2011
|
|
HALL A |
|
|
Session 16
Improving Transplant Outcome in Multiple Myeloma |
|
Should CR be target of therapy in MM? |
|
Chair: P. Sonneveld, The Netherlands |
| 08:30-08:45 |
Yes: S.A. Giralt, USA |
| 08:45-09:00 |
No: B. Barlogie, USA |
| 09:00-09:15 |
Discussion |
|
|
|
Therapy post transplantation in MM |
|
Chair: B. Barlogie, USA |
| 09:15-09:30 |
Pro consolidation: J. Blade, Spain |
| 09:30-09:45 |
Pro maintenance: P. Sonneveld, The Netherlands |
| 09:45-10:00 |
Discussion |
|
|
|
|
Plenary Session 18
Fungal Resistance
Supported by an unrestricted grant from Gilead
|
|
Aspergillus resistance is only seen on the petri dish and not in the patient |
| 10:00-10:05 |
Chair: N. Kröger, Germany |
| 10:05-10:25 |
Pro: H. Hof, Germany |
| 10:25-10:45 |
Con: G. Maschmeyer, Germany |
| 10:45-11:00 |
Discussion |
|
|
|
11:00-11:30 |
Coffee Break |
|
|
|
|
Plenary Session 19
ALL and Intensity of Conditioning Regimen |
|
Is there a role for allo SCT in standard risk ALL? |
|
Chair: D. Niederwieser, Germany |
| 11:30-11:45 |
Yes: J.M. Rowe, Israel |
| 11:45-12:00 |
No: D. Hoelzer, Germany |
| 12:00-12:15 |
Discussion |
|
|
|
Reduced or standard conditioning? |
|
Chair: G. Ehninger, Germany |
| 12:15-12:30 |
Pro reduced: R. Storb, USA |
| 12:30-12:45 |
Pro standard: A. Nagler, Israel |
| 12:45-13:00 |
Discussion |
|
|
|
HALL B |
|
|
Session 17
Infection |
|
Should CMV infection post allo SCT be treated by cell-based therapy? |
|
Chair: S. Riddell, USA |
| 08:30-08:45 |
Yes: H. Einsele, Germany |
| 08:45-09:00 |
No: P. Ljungman, Sweden |
| 09:00-09:15 |
Discussion |
|
|
|
Is combined antifungal therapy more efficient than single agent therapy? |
|
Chair: H. Einsele, Germany |
| 09:15-09:30 |
Yes: N. Keller, Israel |
| 09:30-09:45 |
No: G. Maschmeyer, Germany |
| 09:45-10:00 |
Discussion |
|
|
| |
|
|
|
|
WebStudio.co.il